ClinicalTrials.gg
Active, not recruitingNCT04198922Updated Oct 14, 2026Results posted

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

A Phase 2 interventional study of Acalabrutinib and Questionnaire Administration in Recurrent Moderate-Severe Chronic Graft Versus Host Disease and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Fred Hutchinson Cancer Center. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 14, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Hematologic Neoplasms by Fred Hutchinson Cancer Center — 3 open to participants now, 7 under way, none of them phase 3. Hematologic Neoplasms · Fred Hutchinson Cancer Center.

Enrollment
13th of 24
51 · median 52
Started
2020
with 1 other
Phase 2
9 of 28
1 open now
Registered
22nd of 28
by date

Among the 28 studies in Hematologic Neoplasms by Fred Hutchinson Cancer Center, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2020, is one of 9 in phase 2, and was the 22nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

3 of the 28 studies in Hematologic Neoplasms by Fred Hutchinson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hematologic Neoplasms by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Read the detailed description

OUTLINE:

Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then periodically thereafter.

03

Conditions studied

  • Recurrent Moderate-Severe Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphoid Cell Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • Moderate-severe chronic , diagnosed per the 2014 National Institutes of Health (NIH) criteria
  • Progression or recurrence of active chronic GVHD signs/symptoms after treatment with
  • performance status >= 70%
  • Woman of (WOCBP) who are sexually active must use highly effective methods of during treatment and for 2 days after the last dose of acalabrutinib
  • Men must refrain from sperm donation during the study
  • Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
  • Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information

Exclusion criteria

Exclusion Criteria:

  • Hospitalization for evaluation or management of an infection within the last 8 weeks
  • Change in regimen within the 2 weeks prior to enrollment
  • Noncompliance
  • Treatment of chronic with ibrutinib
  • Received any drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug
  • Recurrent or prior (or any other malignancy that requires active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for >= 2 years
  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the functional classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study
  • Has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease that would limit absorption of oral medication
  • Received a within 28 days of first dose of study drug
  • Known history of infection with (HIV)
  • Uncontrolled, active significant infection (e.g., bacterial, viral, fungal or progressive multifocal leukoencephalopathy)
  • Known history of drug-specific or anaphylaxis to study drug (including active product or components)
  • Active bleeding, history of bleeding diathesis (e.g., hemophilia or von Willebrand disease)
  • Uncontrolled AIHA ( hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)
  • Requires treatment with a strong cytochrome P450 3A4 () inhibitor/inducer
  • Requires warfarin or equivalent vitamin K antagonist
  • History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug
  • Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
  • Subjects who are core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded
  • score of C for hepatic impairment
  • Total > 2 mg/dL or (ALT) > 2 x , unless abnormalities are due to liver GVHD, in which case total bilirubin > 3 mg/dL or ALT 5 x upper limit of normal are exclusions
  • \< 1.0 x 10\^9/L or use of myeloid growth factors within the past 2 weeks
  • count \< 50 x 10\^9/L or platelet transfusion or thrombomimetic agent within the past 2 weeks
  • \< 50 mL/min/1.73 m\^2
  • Breastfeeding or pregnant
  • Concurrent participation in another clinical trial and receiving a non-Food and Drug Administration (FDA) approved medication
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Treatment (acalabrutinib)

    Patients receive acalabrutinib 100 mg PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Acalabrutinib · Other: Questionnaire Administration

Interventions

  • Given PO

    Also known as: 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Best Response (Complete and Partial Response [CR + PR])

    The composite outcome of Complete Response (CR) and Partial Response (PR), calculated according to the proposed therapeutic response in chronic graft-versus-host disease definitions of the 2014 National Institutes of Health Consensus Conference. The observed best Overall Response Rate (ORR) is also compared with the published efficacy of ibrutinib (67%) and the 95% CI for the difference presented.

    Time frame: Within 6 months of start of treatment

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Defined as grade 3 and above according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and all serious AEs (SAEs) described for the population receiving at least one dose of acalabrutinib at least from the time of consent through the safety follow-up period. Any AE/SAE at least possibly related to acalabrutinib therapy will be reported for the duration of the study.

    Time frame: Up to 30 days following the last dose of acalabrutinib

  2. Duration of Response (DOR)

    The median number of weeks a PR or better response (CR) is maintained, among the group achieving at least a PR, calculated from the date of the first response. Will be estimated using the Kaplan-Meier method. Approximate 95% CIs for median DOR will be computed using the formula proposed by Brookmeyer and Crowley.

    Time frame: From the date the PR is documented until loss of the response or start of another systemic immunosuppressive treatment for chronic graft versus host disease (GVHD), whichever occurs first, assessed up to 3 years

  3. Change in Patient-reported Outcomes: Lee Chronic GVHD Symptom Scale Score

    Will be assessed by the Lee Chronic GVHD Symptom Scale score. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).

    Time frame: Baseline up to 6 months

  4. Change in Patient-reported Outcomes: Patient-Reported Outcomes Measurement Information System-29

    Will be assessed by the Patient-Reported Outcomes Measurement Information System-29. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).

    Time frame: Baseline up to 6 months

  5. Failure-free Survival

    Will be defined as the duration of relapse-free survival without adding any other systemic treatment for chronic GVHD. Will be estimated with the composite event of death from any cause, relapse and addition of secondary immune suppressive agents using the Kaplan-Meier method. Systemic immune-suppressive agents include orally or intravenously administered systemically active immune-suppressive drugs, as well as procedures including extra-corporeal photopheresis.

    Time frame: At 6 months and 1 year

  6. Organ-specific Response Rates

    Response rates by organ will also be calculated and reported as ORR (CR+PR) versus all other categories (SD, PD, MR)

    Time frame: Up to 6 months

07

Results

Posted Oct 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Acalabrutinib)
Started50
Completed50
Not completed0

Outcome measures

PrimaryBest Response (Complete and Partial Response [CR + PR])

The composite outcome of Complete Response (CR) and Partial Response (PR), calculated according to the proposed therapeutic response in chronic graft-versus-host disease definitions of the 2014 National Institutes of Health Consensus Conference. The observed best Overall Response Rate (ORR) is also compared with the published efficacy of ibrutinib (67%) and the 95% CI for the difference presented.

Time frame:
Within 6 months of start of treatment
Reported as:
Number · Percentage of participants
Best Response (Complete and Partial Response [CR + PR])
Percentage of participantsTreatment (Acalabrutinib)
Best Response (Complete and Partial Response [CR + PR])62 (47.2 to 75.4)
SecondaryIncidence of Adverse Events (AEs)

Defined as grade 3 and above according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and all serious AEs (SAEs) described for the population receiving at least one dose of acalabrutinib at least from the time of consent through the safety follow-up period. Any AE/SAE at least possibly related to acalabrutinib therapy will be reported for the duration of the study.

Time frame:
Up to 30 days following the last dose of acalabrutinib

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)

The median number of weeks a PR or better response (CR) is maintained, among the group achieving at least a PR, calculated from the date of the first response. Will be estimated using the Kaplan-Meier method. Approximate 95% CIs for median DOR will be computed using the formula proposed by Brookmeyer and Crowley.

Time frame:
From the date the PR is documented until loss of the response or start of another systemic immunosuppressive treatment for chronic graft versus host disease (GVHD), whichever occurs first, assessed up to 3 years
Reported as:
Median · Weeks maintained response
Duration of Response (DOR)
Weeks maintained responseTreatment (Acalabrutinib)
Duration of Response (DOR)28 (8 to 37)
SecondaryChange in Patient-reported Outcomes: Lee Chronic GVHD Symptom Scale Score

Will be assessed by the Lee Chronic GVHD Symptom Scale score. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).

Time frame:
Baseline up to 6 months
Reported as:
Count of participants · Participants
Change in Patient-reported Outcomes: Lee Chronic GVHD Symptom Scale Score
ParticipantsTotalSD + MR + PDCR + PR
Clinically meaningful improvement1028
Stable19613
Clinically meaningful worsening826
SecondaryChange in Patient-reported Outcomes: Patient-Reported Outcomes Measurement Information System-29

Will be assessed by the Patient-Reported Outcomes Measurement Information System-29. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).

Time frame:
Baseline up to 6 months
Reported as:
Count of participants · Participants
Change in Patient-reported Outcomes: Patient-Reported Outcomes Measurement Information System-29
ParticipantsTotalSD + MR + PDCR + PR
PROMIS physical function — Clinically meaningful improvement707
PROMIS physical function — Stable21813
PROMIS physical function — Clinically meaningful worsening927
PROMIS anxiety — Clinically meaningful improvement725
PROMIS anxiety — Stable24519
PROMIS anxiety — Clinically meaningful worsening633
PROMIS depression — Clinically meaningful improvement422
PROMIS depression — Stable24519
PROMIS depression — Clinically meaningful worsening835
PROMIS fatigue — Clinically meaningful improvement707
PROMIS fatigue — Stable19613
PROMIS fatigue — Clinically meaningful worsening1147
PROMIS sleep disturbance — Clinically meaningful improvement725
PROMIS sleep disturbance — Stable23716
PROMIS sleep disturbance — Clinically meaningful worsening514
PROMIS social — Clinically meaningful improvement505
PROMIS social — Stable24717
PROMIS social — Clinically meaningful worsening835
PROMIS pain interference — Clinically meaningful improvement826
PROMIS pain interference — Stable21516
PROMIS pain interference — Clinically meaningful worsening835
SecondaryFailure-free Survival

Will be defined as the duration of relapse-free survival without adding any other systemic treatment for chronic GVHD. Will be estimated with the composite event of death from any cause, relapse and addition of secondary immune suppressive agents using the Kaplan-Meier method. Systemic immune-suppressive agents include orally or intravenously administered systemically active immune-suppressive drugs, as well as procedures including extra-corporeal photopheresis.

Time frame:
At 6 months and 1 year
Reported as:
Number · Percentage of patients
Failure-free Survival
Percentage of patientsTreatment (Acalabrutinib)
FFS at 6 months59 (43.5 to 71.6)
FFS at 1 year37.7 (23.5 to 51.7)
SecondaryOrgan-specific Response Rates

Response rates by organ will also be calculated and reported as ORR (CR+PR) versus all other categories (SD, PD, MR)

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Organ-specific Response Rates
ParticipantsTreatment (Acalabrutinib)
Skin — SD+MR+PD23
Skin — CR+PR10
Skin — Not involved/missing17
Eye — SD+MR+PD20
Eye — CR+PR14
Eye — Not involved/missing16
Mouth — SD+MR+PD11
Mouth — CR+PR17
Mouth — Not involved/missing22
Upper GI — SD+MR+PD1
Upper GI — CR+PR5
Upper GI — Not involved/missing44
GI - Esophagus — SD+MR+PD4
GI - Esophagus — CR+PR5
GI - Esophagus — Not involved/missing41
Lower GI — SD+MR+PD1
Lower GI — CR+PR5
Lower GI — Not involved/missing44
Lung — SD+MR+PD8
Lung — CR+PR6
Lung — Not involved/missing36
Joint — SD+MR+PD13
Joint — CR+PR12
Joint — Not involved/missing25
Liver — SD+MR+PD5
Liver — CR+PR13
Liver — Not involved/missing32

Adverse events

Collected over From enrollment until end of follow-up, up to 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Acalabrutinib)3/50 (6%)16/50 (32%)23/50 (46%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTreatment (Acalabrutinib)
FractureInjury, poisoning and procedural complications3/50
NauseaGastrointestinal disorders2/50
VomitingGastrointestinal disorders2/50
Bacterial infectionInfections and infestations2/50
Viral infectionInfections and infestations2/50
PresyncopeNervous system disorders2/50
Febrile neutropeniaBlood and lymphatic system disorders1/50
Chest painCardiac disorders1/50
PericarditisCardiac disorders1/50
BleedingGastrointestinal disorders1/50
Most frequent other events
Showing 10 of 30
Most frequent other events
EventTreatment (Acalabrutinib)
HeadacheNervous system disorders5/50
Bacterial infectionInfections and infestations3/50
ArrhythmiaCardiac disorders2/50
FatigueGeneral disorders2/50
LymphopeniaInvestigations2/50
NeutropeniaInvestigations2/50
OsteonecrosisMusculoskeletal and connective tissue disorders2/50
Eye painEye disorders1/50
Abdominal painGastrointestinal disorders1/50
DiarrheaGastrointestinal disorders1/50

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment (Acalabrutinib)
Median49 (21 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Acalabrutinib)
Female18
Male32
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Acalabrutinib)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White42
More than one race0
Unknown or Not Reported3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Acalabrutinib)
Hispanic or Latino1
Not Hispanic or Latino48
Unknown or Not Reported1
08

Study locations

6 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Sep 2025, 57 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's 57 months is close to that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2019
First posted
Dec 13, 2019
StartActual
Dec 11, 2020
Primary completionActual
Sep 29, 2025
CompletionEst.
Apr 30, 2027
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedBest responseResponse (completeComplete and partial responsePartial Response [CR + PR])Time frame: Within the first 6 months of treatment when the best response rate is known for each patient → Within 6 months of start of treatment
Oct 14, 2026
Documents
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedIncidence of adverse eventsAdverse Events (AEs)Time frame: Up to 30 days following the last dose of acalabrutinib
  • EditedDuration of responseResponse (DOR)Time frame: From the date the PR is documented until loss of the response or start of another systemic immunosuppressive treatment for chronic graft versus host disease (GVHD), whichever occurs first, assessed up to 3 years
  • EditedChange in patientPatient-reported outcomesOutcomes: Lee Chronic GVHD Symptom Scale scoreScoreTime frame: Baseline up to 3 years → Baseline up to 6 months
  • EditedChange in patientPatient-reported outcomesOutcomes: Patient-Reported Outcomes Measurement Information System-29Time frame: Baseline up to 3 years → Baseline up to 6 months
  • EditedFailure-free survivalSurvivalTime frame: At 6 months and 1 year
  • EditedOrgan-specific response ratesResponse RatesTime frame: Up to 3 years → Up to 6 months
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedBest responseResponse (completeComplete and partial responsePartial Response [CR + PR])Time frame: Within the first 6 months of treatment when the best response rate is known for each patient → Within 6 months of start of treatment
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedIncidence of adverse eventsAdverse Events (AEs)Time frame: Up to 30 days following the last dose of acalabrutinib
    • EditedDuration of responseResponse (DOR)Time frame: From the date the PR is documented until loss of the response or start of another systemic immunosuppressive treatment for chronic graft versus host disease (GVHD), whichever occurs first, assessed up to 3 years
    • EditedChange in patientPatient-reported outcomesOutcomes: Lee Chronic GVHD Symptom Scale scoreScoreTime frame: Baseline up to 3 years → Baseline up to 6 months
    • EditedChange in patientPatient-reported outcomesOutcomes: Patient-Reported Outcomes Measurement Information System-29Time frame: Baseline up to 3 years → Baseline up to 6 months
    • EditedFailure-free survivalSurvivalTime frame: At 6 months and 1 year
    • EditedOrgan-specific response ratesResponse RatesTime frame: Up to 3 years → Up to 6 months
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04198922
Collaborators
AstraZeneca
Responsible party
Stephanie Lee (Professor, Fred Hutchinson Cancer Center) — Principal investigator
First posted
Dec 13, 2019
Start date
Dec 11, 2020
Primary completion
Sep 29, 2025
Completion
Apr 30, 2027 (estimated)
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Study contacts

Stephanie Lee, MD, MPH
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion